Evidence map›Paper›PMID 24180360›Full record

ArticleAIDS research and human retroviruses2014

Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties.

Kathleen M Morrow, Joseph L Fava, Rochelle K Rosen, Sara Vargas, Julia G Shaw, E Milu Kojic, Patrick F Kiser, David R Friend, David F Katz, Project Link Study Team

Abstract read
In one paragraph

Article in AIDS research and human retroviruses, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Achieving the optimal vaginal state: using vaginal products and study gels in Uganda, Zimbabwe, and South Africa.International journal of sexual health : official journal of the World Association for Sexual Health · 2017
    Article
  15. Article
  16. Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.Journal of controlled release : official journal of the Controlled Release Society · 2015
    Review
  17. Article
  18. Vaginal drug distribution modeling.Advanced drug delivery reviews · 2015
    Review
  19. Vaginal deployment and tenofovir delivery by microbicide gels.Drug delivery and translational research · 2015
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kathleen M Morrow1 Centers for Behavioral & Preventive Medicine, The Miriam Hospital , Providence, Rhode Island.
Joseph L Fava
Rochelle K Rosen
Sara Vargas
Julia G Shaw
E Milu Kojic
Patrick F Kiser
David R Friend
David F Katz
Project Link Study Team

Funding

Linking Biophysical Functions of Microbicides to User Perception & AcceptabilityR33MH080591 · NIMH · MIRIAM HOSPITAL · PI GUTHRIE, KATE M · 2008 to 2010
$1.4M
Advancing Reproductive Health: Qualitative Methods & Interdisciplinary MentorshipK24HD062645 · NICHD · MIRIAM HOSPITAL · PI GUTHRIE, KATE M · 2012 to 2016
$689k
Linking Biophysical Functions of Microbicides to User Perception & AcceptabilityR21MH080591 · NIMH · MIRIAM HOSPITAL · PI MORROW, KATHLEEN M · 2006 to 2007
$384k
NICHD NIH HHS K24 HD062645NIMH NIH HHS R21 MH080591NIMH NIH HHS R21/R33 MH080591NIMH NIH HHS R33 MH080591
6 · The paper itself

Abstract

Abstract The effectiveness of any biomedical prevention technology relies on both biological efficacy and behavioral adherence. Microbicide trials have been hampered by low adherence, limiting the ability to draw meaningful conclusions about product effectiveness. Central to this problem may be an inadequate conceptualization of how product properties themselves impact user experience and adherence. Our goal is to expand the current microbicide development framework to include product "perceptibility," the objective measurement of user sensory perceptions (i.e., sensations) and experiences of formulation performance during use. For vaginal gels, a set of biophysical properties, including rheological properties and measures of spreading and retention, may critically impact user experiences. Project LINK sought to characterize the user experience in this regard, and to validate measures of user sensory perceptions and experiences (USPEs) using four prototype topical vaginal gel formulations designed for pericoital use. Perceptibility scales captured a range of USPEs during the product application process (five scales), ambulation after product insertion (six scales), and during sexual activity (eight scales). Comparative statistical analyses provided empirical support for hypothesized relationships between gel properties, spreading performance, and the user experience. Project LINK provides preliminary evidence for the utility of evaluating USPEs, introducing a paradigm shift in the field of microbicide formulation design. We propose that these user sensory perceptions and experiences initiate cognitive processes in users resulting in product choice and willingness-to-use. By understanding the impact of USPEs on that process, formulation development can optimize both drug delivery and adherence.

Indexed as

Drug MonitoringAdministration, IntravaginalAdultAnti-Infective Agents, LocalDrug Delivery SystemsFemaleHIV InfectionsHumansMenstrual CycleVaginaVaginal Creams, Foams, and JelliesYoung AdultAnti-Infective Agents, LocalVaginal Creams, Foams, and Jellies

Identifiers

PMID24180360
PMCPMC3931431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.